Datasheet

LZTS2 Antibody
CATALOG NUMBER: 6635

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Rat: (95%), Bovine: (95%)
TESTED APPLICATIONS:IF
APPLICATIONS:LZTS2 antibody can be used for detection of EPAC1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1305 - Human Kidney Tissue Lysate
 2) Cat. No. 10-401 - Human Kidney Tissue Slide
SPECIFICITY:LZTS2 antibody is predicted to not cross-react with other LZTS family members
IMMUNOGEN:LZTS2 antibody was raised against a 19 amino acid synthetic peptide near the amino terminus of human LZTS2.

The immunogen is located within amino acids 80 - 130 of LZTS2.
HOST SPECIES:Rabbit

Properties

PURIFICATION:LZTS2 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:LZTS2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:LZTS2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:LZTS2 Antibody: LAPSER1, KIAA1813, LAPSER1, Leucine zipper putative tumor suppressor 2, Protein LAPSER1, hLZTS2
ACCESSION NO.:NP_115805
PROTEIN GI NO.:45331215
OFFICIAL SYMBOL:LZTS2
GENE ID:84445

Background

BACKGROUND:LZTS2 Antibody: The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1), a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.
REFERENCES: 1) Thyssen G, Li TH, Lehmann L, et al. LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol. Cell. Biol. 2006; 26:8857-67
2) Sudo H and Maru Y. LAPSER1/LZTS2: a pluripotent tumor suppressor linked to the inhibition of katanin-mediated microtubule severing. Hum. Mol. Genet. 2008; 17:2524-40.
3) Sudo H and Maru Y. LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 Katanin. FASEB J. 2007; 21:2086-100.
4) Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, et al. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 2001; 20:6707-17.

For Research Use Only